Stage IIB Prostate Cancer AJCC v8
24
3
13
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
12.5%
3 terminated out of 24 trials
57.1%
-29.4% vs benchmark
8%
2 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (24)
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans
Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners
RElugolix VErsus LeUprolide Cardiac Trial
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their Partners
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer
Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer